financetom
Business
financetom
/
Business
/
Lenskart to hire over 2,000 persons by 2022
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lenskart to hire over 2,000 persons by 2022
Aug 11, 2021 6:36 AM

Omnichannel eyewear brand Lenskart on Wednesday said it plans to expand its workforce and add over 2,000 employees across the country by March 2022. In addition, Lenskart will also expand its international teams in Singapore, West Asia, and the US by adding 300 more employees.

Share Market Live

NSE

Lenskart has been aggressively hiring across verticals, especially the tech and data science team, roping in data scientists, business analysts, data engineers, and experts, a statement said. The company is looking to add 1,500 more retail employees "to manage their rapidly increasing stores" and over 100 engineers to the technology team across Bengaluru, NCR, and Hyderabad, it added.

Over 300 employees will join the supply chain and manufacturing operations, while another 100 people will be hired for corporate functions across finance, consumer insights, human resources, and merchandising. Lenskart founder and CEO Peyush Bansal said the company has continued to grow exponentially in international markets as well as in India, and it is building a strong presence in regional markets as well through its stores and e-commerce.

"This has opened up several job opportunities across Lenskart to serve and delight our customers at a huge scale. So, hiring is a key aspect in our growth journey and we are looking at actively hiring skilled talent across verticals for regions like Hyderabad, Bengaluru, Mumbai, and Delhi, among others," he added.

The company said it currently has over 5,000 employees, including over 200 engineers, data scientists, and product designers. Founded in 2010, Lenskart has raised funds from investors including KKR, SoftBank Vision Fund, PremjiInvest, and IFC, among others.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved